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Abstinence from chronic ethanol consumption leads to the manifestation of a variety of symptoms attributed to
central nervous system hyperexcitability, such as increased irritability, anxiety, and restlessness. Recent studies have
demonstrated the importance of metabotropic glutamate receptor 5 (mGluR5) in addictive behaviours. This study
investigates the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on ethanol withdrawal
induced anxiety using two behavioural paradigms. Male Wistar rats were fed a Modified Liquid Diet (MLD)
containing low fat cow milk, sucrose, and maltodextrin with a gradual introduction of 2.4%, 4.8% and 7.2% ethanol
for 20 days. Six hours into ethanol withdrawal, the rats were intraperitoneally injected with normal saline and MPEP
(2.5, 5.0, 10, 20, 30 mg/kg) and were assessed for ethanol withdrawal induced anxiety-like syndrome using an
automated elevated plus maze and an open field. MPEP at 10 mg/kg significantly attenuated ethanol withdrawal
induced anxiety without any compromising effects on locomotor activities. Despite reversing several indices of
ethanol withdrawal induced anxiety in both the elevated plus maze and the open field, low doses of MPEP
(2.5, 5 mg/kg) significantly compromised the locomotor activities of ethanol withdrawn rats. High doses of MPEP
(20 and 30 mg/kg) significantly attenuated withdrawal anxiety when tested in the elevated plus maze but not in
the open field. Administration of MPEP (2.5, 5, 10, 20, 30 mg/kg) has no significant compromising effect on the
locomotor activities of ethanol naïve rats. Despite significantly reducing withdrawal anxiety in both behavioural
paradigms at 10 mg/kg, the compromising effects of low and high doses of MPEP must be further explored along
with the therapeutic efficiency of this drug for relieving withdrawal induced anxiety.
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Glutamate is the most abundant excitatory neurotransmit-
ter in the mammalian brain. The excitatory functions of
glutamate are categorised into two types, fast and slow.
The fast excitatory actions of glutamate are mediated by
ionotropic N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-ioxyzole-4-propionicacid (AMPA), and
kainate (KA) receptors. The slow glutamate responses are
mediated by metabotropic glutamate receptors (mGluRs)
through G-protein coupling with numerous intracellular
signalling cascades that can modulate ionotropic receptor* Correspondence: jaykumar5453@gmail.com
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reproduction in any medium, provided the orfunction [1]. According to sequence homology, effector
coupling, and pharmacology, mGluRs are divided into three
subgroups. The group I mGluRs, metabotropic glutamate
receptor 1 (mGluR1) and metabotropic glutamate receptor
5 (mGluR5), are positively coupled to phospholipase C and
the group II mGlu receptors (mGlu2and mGlu3), and the
group III receptors (mGlu4, mGlu6, mGlu7, and mGlu8)
are negatively coupled to adenylate cyclase [2]. Among
these mGluRs, mGluR5 has been shown to play an import-
ant role in ethanol seeking and relapse-like behaviours [3].
Additionally, 6-methyl-2-(phenylethynyl)-pyridine (MPEP),
a selective mGluR5 antagonist, has been shown to reduce
ethanol consumption [4], inhibit the onset and mainten-
ance of ethanol self-administration [5], and reduce binge
ethanol intake in the drinking in the dark paradigm [6].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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using several models of anxiety [7-9]. This present study
addresses the importance of mGluR5 in both ethanol
dependence and anxiety by exploring the role of mGluR5
in ethanol withdrawal induced anxiety. The anxiety-like
syndrome that appears during abstinence from chronic
ethanol exposure is an unpleasant feeling or negative
emotional response accompanied by an increased gluta-
matergic neurotransmission [10]. This anxiety-like syn-
drome can contribute to an enhanced risk of relapse
[11,12]. A limited number of studies has implicated the
importance of mGluR5 in the manifestation of ethanol
withdrawal induced anxiety-like syndrome [13]. Acampro-
sate, an FDA approved drug for the treatment of alcohol
use disorders, has been shown to alter glutamatergic neuro-
transmission via a weak antagonism of NMDA receptors
[14] and by an indirect blockade of the mGlu5 receptor
[15]. The present study used MPEP, which is a selective
mGluR5 antagonist of the human mGluR5a receptor with
an IC 50 value of 36 nM, in a PI hydrolysis assay without
any significant effect at other metabotropic or ionotropic
glutamate receptors. MPEP has not shown agonist activity
on group II mGluRs and readily penetrates the blood–
brain barrier [16].
To investigate the role of mGluR5 in the manifestation
of ethanol withdrawal induced-anxiety like syndrome,
rats were exposed to chronic ethanol for 20 days using a
Modified Liquid Diet (MLD) containing ethanol to create
alcohol dependence. The rats were subsequently injected
with respective doses of intraperitoneal (IP) saline and
MPEP (2.5, 5.0, 10, 20, 30 mg/kg i.p) after six hours of
withdrawal. Next, the rats were tested for ethanol with-
drawal induced anxiety using an automated elevated
plus maze system and an open field.
Methods
Animal preparation
All experiments were performed using male Wistar rats
weighing 250-300 g obtained from the Laboratory Animal
Research Unit, Universiti Sains Malaysia (LARUSM) and
were maintained in a 12 h light–dark cycle with the lights
on between 1900–0700. The animals were housed indi-
vidually and kept at a constant room temperature of 24°C
and were allowed to adapt to the surroundings for at
least 7 days prior to the experiment. All of the animal
procedures in this study were approved by the Animal
Ethics Committee of Universiti Sains Malaysia.
The animals were allocated into 7 groups for each study
(n = 56). Group 1: The rats were given MLD without
ethanol (n = 8). Group 2 (n = 8) consisted of rats that
were fed MLD with ethanol and were given an injection
(i.p.) of normal saline 6 hours after the last ethanol
intake. Group 3, 4, 5, 6, and 7 (n = 8/group) consisted
of rats that received MLD with ethanol and receivedMPEP (2.5, 5, 10, 20 and 30 mg/kg, respectively) dur-
ing withdrawal.
The rats were individually housed and were fed with an
MLD without ethanol for 7 days in special glass bottles
to prevent spillage. Group 1 was given an MLD without
ethanol throughout the experiment. The rats had access
to MLD for 24 hours a day. The MLD was prepared fresh
and given in spillage free special drinking bottles twice per
day as a sole diet at 0900 and 1900. At the end of 7 days,
ethanol was gradually introduced into the MLD for groups
2, 3, 4, 5, 6, and 7 from 2.4% (3 days) to 4.8% (3 days) and
7.2% (14 days). When the ethanol concentration was
increased, the sucrose and maltodextrin was reduced
to maintain isocaloricity of the diet. The daily ethanol
intake was measured twice per day at the same time for all
rats and was expressed as grams per kilogram per day.
After 20 days of chronic ethanol consumption, the ethanol
was removed from the MLD and was replaced with su-
crose and maltodextrin.
The effects of MPEP alone on anxiety and locomotor
activity in the open field was carried out by measuring
the time spent in the central zone and number of lines
crossed in the open field by ethanol naive rats. Similarly,
the effect of MPEP alone on anxiety (percent open arm
total time and entries) and locomotor activities (basic
movement, fine movement, X ambulation, Y ambulation)
in the EPM was assessed for 5 minutes following MPEP
administration (2.5, 5, 10, 20, and 30 mg/kg). Approxi-
mately 6 hours after the last ethanol intake and one
hour before the behavioural testing, ethanol withdrawn
rats were administered with MPEP (i.p.) and were brought
to the behavioural study room. Each rat was handled care-
fully and consistently to minimise any sort of stress prior to
behaviour testing.
Elevated plus maze
The automated maze (Kinder Scientific, Poway, CA) con-
sisted of two open arms (width, 10.8 cm, length, 50.17 cm)
and two closed arms (width, 10.8 cm, length, 50.17 cm,
walls, 40.01 cm) with a central platform (10.8cmx10. 8 cm).
The maze was elevated 85.09 cm from the floor, and the rat
movements were tracked by infrared photobeams embed-
ded along the entire length of the base of each arm. The
movements were subsequently analysed by Motor Monitor
computer software. The locomotion of ethanol dependent
and non-dependent rats in the maze was measured using
an ambulation (a measure used to express larger animal
movements) algorithm. The automated elevated plus maze
was equipped with one Anchor Beam for each dimension,
one X Anchor Beam and one Y Anchor Beam. The Anchor
Beam is the lowest beam blocked in a dimension. The
Anchor Beam is reset when an animal ambulates. An
ambulation occurs when a new beam block occurs, and
the anchor beam for that dimension is released before
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and then X5 is blocked, the new beam break at X5 will
be counted as an ambulation. Otherwise, the break at
X5 is recorded as a fine movement. Fine movement is
used to express smaller animal movements, such as
grooming and head movements. Fine movement is re-
corded when a subject changes a beam status but the
change does not fit the definition of an ambulation.
The fine movement counter is incremented when the
beam status change does not meet the ambulation algo-
rithm. Basic movement is the simple tally of all horizontal
beams in the system. The basic movement counter is incre-
mented upon each new beam block. The experiments were
conducted during the dark phase of a light–dark cycle in a
quiet room with homogenous illumination (2–4 lx) directed
towards the apparatus [17]. The experiment was initiated
by placing the rat in the centre of the maze platform facing
an open arm and was followed by recording the activity of
the rat in the maze for 5 minutes of a single session for
each rat. The maze was wiped clean after each test session.
The ethanol withdrawal induced anxiety was measured
as the time spent in open arms as a percent of the total
time spent exploring both the open and closed arms
(Open Arms Total Time Percentage) and the number
of entries into the open arms as a percentage of the
total number of entries into both open and closed arms
(Open Arms Entries Percentage). The effects of MPEP
alone on anxiety was measured by measuring the per-
cent open arm total time and entries produced by etha-
nol naive rats.
Open field test
The open field consisted of a square box that measured
60x60cm with 35 cm walls. Lines were drawn on the floor
into 15x15cm squares and were visible through the clear
Plexiglas floor. The test arena was divided into central
and peripheral zones. Each rat was placed in the central
area and was allowed to explore for 5 minutes. After the
5 minute test, the rats were returned to the home cages,
and the open field was cleaned thoroughly and allowed
to dry between tests. The apparatus was placed under a
homogenous illumination (14–20 lx) [17]. The performance
in the open field was scored by video. The number of
lines crossed by the ethanol dependent and non-dependent
rats for 5 minutes in the open field was recorded as a
measurement for locomotor activities where all 4 paws
required crossing a line for a count to occur. Ethanol
withdrawal induced anxiety was recorded by measur-
ing the percentage of time spent in the central zone
and the number of entries produced in the central zone
of the open field. The effects of MPEP alone on anxiety
was assessed by measuring the percent total time spent
in the central zone of the open field by ethanol naive
rats following MPEP treatment.Drugs
The mGluR5 antagonist MPEP (2-methyl-6-(phenylethynyl)-
pyridine) was purchased from Tocris, UK. The drug was
freshly dissolved in physiological saline, and injected i.p.
MPEP was administered in the doses of 2.5, 5, 10, 20 or
30 mg/kg (2 ml/kg). Ethanol was purchased from Hamburg
Chemicals, and ethanol stock solutions were prepared
by mixing appropriate volumes of ethanol (95.6% v/v) and
distilled water. The dose range of the drug and the time of
administration were chosen based upon [18]. The dose
2.5 mg/kg MPEP was chosen for ethanol naive rats based
on a previous study [9] and our preliminary study.
Modified liquid diet (MLD)
The composition of the MLD with ethanol was low fat cow
milk (12%), ethanol 95.6% (2.4, 4.8, and 7.2% of the solution),
maltodextrin (10.35%) and 17 g sucrose. The final volume
of the MLD was maintained at 1 L. MLD without ethanol
was isocaloric to MLD with ethanol and contained sucrose
and maltodextrin as a caloric substitute for ethanol. This
mixture supplied 1070 kcal l-1 and was a modification of
the MLD proposed by Uzbay and Kayaalp [19].
Blood ethanol level measurement
Tail blood collection
Tail blood samples (0.5 ml) were taken from a separate
individual group of rats (n = 20) that were fed MLD con-
taining ethanol for 20 days. The blood sample was taken
immediately after removing ethanol from the liquid diet
[19] and were centrifuged to obtain the sera. The sera
were sent to the Doping Control Centre, USM Penang
to measure the blood ethanol levels. The blood ethanol
levels were measured using a Gas Chromatograph(y) Flame
Ionisation Detector (GC FID).
Chemicals and reagents (blood ethanol level measurement)
Deionised water (18 MΩ cm resistivity) was obtained from
Elga Purelab water purification system (ELGA, UK).
Alcohol (Ethyl Alcohol with purity 99.4%) was supplied by
Fisher Scientific, and 1-propanol (Internal Standard), purity
99.5%, was obtained from Merck.
Instruments
The 20 mL headspace vials were incubated in a headspace
autosampler (Agilent G1888 headspace Sampler) at 70°C
for 15 min. After equilibration, 0.2 ml of the headspace vial
was pressurised into the GC/FID. The loop and transfer line
temperatures were set at 75°C and 80°C, respectively. Alco-
hol analysis was performed with an Agilent Flame ionisation
detector (FID) (Agilent, USA) equipped with Agilent GC
6890 series (Agilent, USA). The column used was an Agilent
HP5 fused silica capillary column (30 m x 0.32 mm, film
thickness 0.32 um). The injector and detector temperatures
were 200°C and 250°C, respectively. Hydrogen (40 mL/min)
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isothermal 50°C for 5 min. The retention time for alco-
hol was 3.17 min, and the retention time for 1-propanol
(Internal Standard) was 3.25 min. Good linearity (r2 > 0.99)
was obtained, and the blood ethanol assay was performed
in triplicate of each sample [20].
Statistical analysis
Data were expressed as the mean ± SEM. Data for the
final average ethanol intake, elevated plus maze study
and open field test were analysed by one way analysis of
variance (ANOVA), and the differences between individ-
ual means were compared with a post hoc Tukey’s Test.
p < 0.05 was considered to be statistically significant.
Results
Ethanol consumption and blood ethanol level
The average ethanol intake for 20 days ranged from
10.1 ± 0.7 to 10.9 ± 0.4 g/kg-1 day-1 (Table 1). There were
no significant differences in the amount of ethanol
consumed between groups [F(6,49) = 0.357; p > 0.05].
The blood ethanol level of the ethanol fed rats was
283.1 ± 14.5mgdl-1(n = 20) just before abstinence.
Basic movement
The basic movement was recorded by monitoring rat
behaviour in the automated elevated plus maze. One
Way Analysis of Variance (ANOVA) revealed a significant
reduction in the basic movement of the ethanol fed rats
compared to control rats [F(6,49) = 20.975; p < 0.0001]
(Figure 1A). Administration of 2.5 and 5 mg/kg MPEP
resulted in a significant reduction in the basic move-
ment compared to dose of 30 mg/kg MPEP. However,
there were no significant differences recorded between
the vehicle and MPEP (10, 20, 30 mg/kg) treated ethanol
fed rats (Figure 1A).
Fine movement
Fine movement was obtained by assessing the activity of
the rats in the automated elevated plus maze. A significant
reduction in the fine movement of ethanol fed rats was
observed compared to the control rats [F(6,49) = 13.548;Table 1 Average ethanol intake
Group Ethanol intake(g/kg day-1)
Ethanol Withdrawal (EW) 10.2 ± .5
EW + 2.5MPEP 10.5 ± .4
EW + 5MPEP 10.9 ± .4
EW + 10MPEP 10.2 ± .4
EW + 20MPEP 10.4 ± .2
EW + 30MPEP 10.1 ± .7
Table 1 shows average ethanol intake (20 days) of the animals employed in
the behavioral study, One Way Analysis of Variance.p < 0.0001] (Figure 1A). Administration of 2.5 mg/kg MPEP
resulted in a significant reduction in fine movement
compared to ethanol withdrawal and MPEP at doses of
10 and 30 mg/kg. Significant differences in fine movement
were recorded between animals given 5 mg/kg MPEP and
10 mg/kg MPEP. However, there were no significant differ-
ences between the vehicle and MPEP (10, 20, 30 mg/kg)
treated ethanol fed rats (Figure 1A).
X and Y ambulation
Similar to both basic and fine movements, a significant
reduction in X ambulation (closed arm) of ethanol fed rats
was observed compared to control rats [F(6,49) = 19.456;
p < 0.0001] (Figure 1B). There were no significant differ-
ences between the ethanol withdrawn group and the MPEP
(2.5, 5, 10, 20, 30 mg/kg) treated rats (Figure 1B). Likewise,
Y ambulation (open arm) of ethanol withdrawn group is
significantly lower than the Y ambulation of the control
group [F(6,49) = 13.173; p < 0.01] (Figure 1B).
Open Arm total time (%)
Figure 2A illustrates a significant decrease in the total
time spent in the open arms of the elevated plus maze in
the ethanol withdrawn rats compared to rats fed MLD
without ethanol [F(6,49) = 20.309; p < 0.0001]. The post
Hoc analysis revealed a significant increase in the time
spent in the open arms compared to the ethanol with-
drawal group following administration of 2.5, 5, 10, 20, and
30 mg/kg MPEP. During ethanol withdrawal, rats treated
with 5 and 10 mg/kg of MPEP spent significantly more
time in the open arms of the elevated plus maze than
rats treated with 2.5 mg/kg MPEP (Figure 2A).
Open Arm entries
Similar to the open arm total time percentage, a decrease
in the entries in the open arms of the elevated plus maze
was reported in ethanol withdrawn rats compared to rats
fed MLD without ethanol [F(6,49) = 15.565; p < 0.0001]
(Figure 2B). Post hoc analysis revealed a significant increase
in the open arm entries following the administration
of 10, and 30 mg/kg MPEP compared to the ethanol
withdrawn group. During abstinence, rats treated with
10 mg/kg MPEP produced significantly more entries
in the open arm of the maze compared to animals given
2.5, 5, 20 and 30 mg/kg MPEP.
Closed Arm entries
Figure 2B shows a decrease in the closed arm entries of
the elevated plus maze in ethanol withdrawn rats com-
pared to rats fed MLD without ethanol [F(6,49) = 41.044;
p < 0.0001]. Administration of 2.5 mg/kg MPEP resulted
in a significant decrease in the closed arm entries compared
to ethanol withdrawal group shown by post hoc analysis.
However, there were no significant changes in the closed
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Figure 1 The effect of MPEP on the locomotion of ethanol withdrawn rats. The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on basic and
fine movement (A), X and Y ambulation (B) in the automated elevated plus maze of ethanol withdrawn rats after 7 hours of withdrawal. Each
column represents the mean ± S.E.M [n = 8 for each group; EN = Control rats fed MLD without ethanol and treated with saline; EW = Ethanol
Withdrawal (the ethanol withdrawn group treated with normal saline); EW + 2.5, EW + 5,EW + 10, EW + 20, EW + 30 MPEP = ethanol withdrawn
group treated with respective doses of MPEP (mg/kg); **p < 0.01,***p < 0.001 vs EN; #p < 0.05 vs EW; αp < 0.05, ααp < 0.001 vs 2.5 mg/kg MPEP;
βp < 0.05 vs 5 mg/kg MPEP, One Way Analysis of Variance and post hoc Tukey’s test].
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30 mg/kg) treated ethanol withdrawn rats (Figure 2B).
Basic and fine movement of ethanol naïve rats
Figure 3A shows the effect of MPEP (2.5, 5, 10, 20,
30 mg/kg) on the basic movement of ethanol naïve
rats. Neither doses of MPEP produced any significant
effect on the basic movement of the ethanol naïve
rats [F(5,42) = 0.892; p > 0.05] (Figure 3A). Likewise, MPEP
(2.5, 5, 10, 20, 30 mg/kg) had no significant effect on
the fine movement of ethanol naïve rats [F(5,42) = 1.767;
p > 0.05] (Figure 3A).X and Y ambulation of ethanol naïve rats
Figure 3B shows the effect of MPEP (2.5, 5, 10, 20, 30 mg/kg)
on the X ambulation of the ethanol naïve rats. Neither
doses of MPEP produced any significant effects on the X
ambulation of ethanol naïve rats [F(5,42) = 1.936; p > 0.05]
(Figure 4A). Similarly, MPEP (2.5, 5, 10, 20, 30 mg/kg)
had no significant effect on the Y ambulation of the ethanol
naïve rats [F(5,42) = 2.312; p > 0.05] (Figure 3B).
Central zone total time (%)
The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on the
percentage of total time spent in the central zone of the
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Figure 2 The effect of MPEP on open and closed arm behaviours. The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on percent total time
spent in the open arms (A), and the open and closed arm entries (B)of the automated elevated plus maze of ethanol withdrawn rats 7 hours
after withdrawal. Each column represents the mean ± S.E.M [n = 8 for each group; EN = Control rats fed MLD without ethanol and treated with
saline; EW= Ethanol Withdrawal (ethanol withdrawn group treated with normal saline); EW+ 2.5, EW+ 5,EW+ 10, EW+ 20, EW+ 30 MPEP = ethanol
withdrawn group treated with respective doses of MPEP (mg/kg);*p < 0.05,**P < 0.01, ***p < 0.001 vs EN; #p < 0.05, ##p < 0.01,###p < 0.001 vs EW;
αp < 0.05, αααp < 0.001 vs 2.5 mg/kg MPEP; βββp < 0.001 vs 5 mg/kg MPEP; μμμp < 0.001 vs 20 mg/kg MPEP; $$p < 0.01 vs 30 mg/kg MPEP,One Way
Analysis of Variance and post hoc Tukey’s test].
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One Way Analysis of Variance (ANOVA) reveals a signifi-
cant decrease in total time spent in the central zone of the
open field in the ethanol withdrawn rats compared to rats
fed MLD without ethanol [F(6,49) = 13.995; p < 0.0001]
(Figure 4A). Post Hoc analysis revealed a significant in-
crease in the time spent in the central zone compared to
ethanol withdrawal group following administration of 2.5, 5,
and 10 mg/kg MPEP. However, treatment of ethanol with-
drawn rats with MPEP (20, 30 mg/kg) did not significantly
affect the time spent in the central zone of the open field.
Central zone entries (%)
As seen in Figure 4B, the ethanol withdrawn rats exhibited
a decrease in the entries in the central zone of the openfield (statistically insignificant) compared to the ethanol
naïve rats [F(6,49) = 2.889; p < 0.05]. No dose of MPEP
(2.5, 5, 10, 20, 30 mg/kg) significantly affected the per-
centage of central zone entries in the open field. How-
ever, post hoc analysis revealed that administration of
30 mg/kg MPEP resulted in a significant reduction in
central zone entries compared to normal rats.
Open Arm total time and entries in ethanol naive rats(%)
Figure 5A shows the effect of MPEP on percentage
of open arm total time and entries in ethanol naive
rats. MPEP (2.5, 5, 10, 20, 30 mg/kg) significantly in-
creased the total time spent in the open arm of the
maze [F(5,42) = 14.455; p < 0.001]. However, only rats
administered MPEP (5, 10 mg/kg) significantly increased
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Figure 3 The effect of MPEP on locomotion of ethanol naïve rats. The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on basic and fine
movement (A), X and Y ambulation (B) in automated elevated plus maze of ethanol naïve rats. Each column represents the mean ± S.E.M [n = 8
for each group; EN = Control rats fed MLD without ethanol and treated with saline; EN + 2.5,EN + 5,EN + 10, EN + 20, EN + 30MPEP = ethanol naive
group treated with respective doses of MPEP (mg/kg); One Way Analysis of Variance].
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3.079; p < 0.05].
Central zone total time in ethanol naive rats (%)
Figure 5B exhibits the effects of MPEP on percentage
of time time spent in central zone of the open field by
ethanol naive rats. MPEP (2.5, 10 mg/kg) significantly
increased the percentage of time spent in the central
zone of the open field [F(5,42) = 3.073, p < 0.05).
Lines crossed
The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on
number of lines crossed in the open field by ethanol
withdrawn rats is shown in Figure 6A. One Way Analysis
of Variance (ANOVA) revealed a significant decrease
in the number of lines crossed in the open field by the
ethanol withdrawn rats compared to rats fed MLD with-
out ethanol [F(6,49) = 14.543; p < 0.001]. No dose of MPEP
(2.5, 5, 10, 20, 30 mg/kg) had a significant effect on thenumber of lines crossed in the open field during ethanol
withdrawal. Figure 6B shows the effect of MPEP (2.5, 5,
10, 20, 30 mg/kg) on the number of lines crossed by etha-
nol naïve rats in the open field. No significant difference
was reported between the control and the MPEP treated
ethanol naïve rats [F(5,42) = 2.43; p > 0.05].
Discussion
The liquid diet technique was chosen as a method of
ethanol administration in this study as this is the most
comparable and relevant model for ethanol consumption
in humans [19]. The lack of group differences in the aver-
age ethanol intake (Table 1) prior to drug administration
negates the contribution of pre-existing differences in
ethanol exposure to the dose dependent effects of the
antagonist on anxiety. This current study demonstrates
the anxiolytic property of MPEP using the anxiety models
of the automated elevated plus maze and the open field
test. Evaluation of animal behaviour in the elevated plus
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Figure 4 The effect of MPEP on open field behaviours. The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on the percent total time (A) and
the entries (B) produced in the central zone of the open field by ethanol withdrawn rats 7 hours after withdrawal. Each column represents the
mean ± S.E.M [n = 8 for each group; EN = Control rats fed MLD without ethanol and treated with saline; EW = Ethanol Withdrawal
(ethanol withdrawn group treated with normal saline); EW + 2.5, EW + 5,EW + 10, EW + 20, EW + 30MPEP = ethanol withdrawn group treated with
respective doses of MPEP (mg/kg); *p < 0.05, ***p < 0.001 vs EN; #p < 0.05, ###p < 0.001 vs EW, One Way Analysis of Variance and post hoc
Tukey’s test].
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drive of rodents in a novel environment and the aversion to
open spaces. Anxious animals spend more time in the
closed arms, while less anxious animals explore the open
arms longer [21]. However, the anxiety-like behaviour in
the open field is demonstrated through the conflict between
exploration and the aversion against open, bright areas [22].
An important feature of rats in this anxiety model is trav-
eling close to the wall, which confers security, while the
centre is anxiogenic [23]. Anxious rodents spend more time
in the corner and at the periphery of the arena as a naturaltendency of avoidance reaction. A considerable amount of
literature on ethanol withdrawal induced anxiety has been
published using these models [24,25]. Both tests assess the
unconditioned response to aversive environments; however,
the findings of previous studies corroborate the idea that
these tests measure different aspects of anxiety [26,27].
Our study demonstrates that withdrawal from ethanol
following 20 days of chronic ethanol consumption induced
an anxiety-like state in rats when tested in the automated
elevated plus maze and the open field. This ethanol with-
drawal induced anxiety was observed as a decrease in the
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Figure 5 The effect of MPEP on the anxiety of ethanol naïve rats in the automated elevated plus maze and open field. The effect of
MPEP (2.5, 5, 10, 20, and 30 mg/kg) on the percent open arm total time and entries of the automated elevated plus maze (A) and percentage of
total time spent in the central zone of the open field by ethanol naïve rats (B). Each column represents the mean ± S.E.M [n = 8 for each group;
EN = Control rats fed MLD without ethanol and treated with saline; EN + 2.5, EN + 5, EN + 10, EN + 20, EN + 30MPEP = ethanol naive group
treated with respective doses of MPEP (mg/kg); *p<0.05, **p<0.01, ***p< 0.001 vs EN, One Way Analysis of Variance and post hoc Tukey’s test].
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http://www.behavioralandbrainfunctions.com/content/9/1/43percentage of open arm total time, the open arm entries,
the central zone total time, the central zone entries, and the
locomotion. Our study indicated that 10 mg/kg of MPEP
(i.p) increased the open arm total time, the open arm en-
tries, and central zone total time percentage in ethanol
withdrawn rats. MPEP at 30 mg/kg produced a significant
anxiolytic effect in ethanol withdrawn rats when tested in
the automated elevated plus maze. This significant effect
of MPEP in reducing anxiety at 10 mg/kg is similar to some
previous findings [8,9]. These previous studies reported
the anxiolytic properties of MPEP in normal rats, while
our study is reporting the anxiolytic properties of MPEP
using an ethanol withdrawal model for the first time. Our
study recorded significant anxiolytic effects of MPEP at
2.5 mg/kg in ethanol naive rats. However, the significant
anti-anxiety effect of MPEP in reversing withdrawal
anxiety occurred at 10 and 30 mg/kg MPEP when testedin the elevated plus maze (both percent open arm total
time and entries). These discrepancies in dose responses
clearly indicate the possibilities of changes in mGluR5
expression or function during ethanol withdrawal as
suggested previously by Olive and Becker [28]. Chronic
exposure to an ethanol containing liquid diet decreased
mGluR5 mRNA levels in the dentate gyrus and CA3 re-
gions of the rat hippocampus [29]. Another study using
a mature organotypic hippocampal slices demonstrated
an increase in mGluR5 (not significant), and the NR1 and
NR2B subunits of NMDARs following 10 days of ethanol
exposure [30]. Another study by Obara and colleagues
reported an increase in the expression of mGluR5 in
the nucleus accumbens and the central amygdala of P
(alcohol-preferring) rats following chronic ethanol con-
sumption and withdrawal [31]. Acutely, ethanol inhibits
the function of both NMDA and mGluRs [32,33]. Thus,
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Figure 6 The effect of MPEP on the number of lines crossed in open field. The effect of MPEP (2.5, 5, 10, 20, and 30 mg/kg) on the number
of lines crossed in the open field by ethanol withdrawn rats 7 hours after withdrawal (A) and ethanol naïve rats (B). Each column represents the
mean ± S.E.M [n = 8 for each group; (A) EN = Control rats fed MLD without ethanol and treated with saline; EW = Ethanol Withdrawal (ethanol
withdrawn group treated with normal saline); EW + 2.5, EW + 5,EW + 10, EW + 20, EW + 30MPEP = ethanol withdrawn group treated with
respective doses of MPEP (mg/kg); (B) EN + 2.5, EN + 5,EN + 10, EN + 20, EN + 30MPEP = ethanol naive group treated with respective doses of
MPEP (mg/kg); ***p < 0.001 vs EN, One Way Analysis of Variance and post hoc Tukey’s test].
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increase in the expression and the sensitisation of acutely
inhibited glutamate receptors [34]. Contrary to previous
studies where low doses of MPEP were sufficient to
demonstrate significant anxiolytic property [8,9], this study
demonstrates significant anti-anxiety effects of MPEP at
moderate and high doses when tested in the elevated plus
maze. Thus, the results of this study indirectly corroborate
the findings of the previous works that demonstrated the
upregulation of mGluR5 following chronic ethanol intake.
Another finding of this study was that MPEP at high
doses had no significant effect on any indices of with-
drawal anxiety when tested in the open field but showingsignificant anxiolytic effects in the automated elevated plus
maze. MPEP at a dosage of 30 mg/kg was recommended
by (Anderson et al., 2003) for a maximum effect, but no
significant effect on ethanol withdrawal induced anxiety
was recorded at either 20 or 30 mg/kg when tested in
the open field. This contradicting treatment effect observed
in different tests might be due to differences in the psycho-
biological meanings of various tests [35,36]. For example,
chlordiazepoxide produced anti-anxiety effects in elevated
plus maze but not in the open field in Lewis rats. This
inter-test variation suggests that the construct differences
between these tests assess different aspects of anxiety
[26,27]. Thus, the variations in dose effects observed in this
Kumar et al. Behavioral and Brain Functions 2013, 9:43 Page 11 of 13
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two behavioural paradigms. In addition, the possible off
target effects of MPEP at high doses could influence the
animal behaviours observed in this study. According to
O’Leary et al. [37], MPEP is a non-competitive NMDA
receptor antagonist and decreases NMDA or glutamate-
induced neurotoxicity through NMDA antagonism.
Another study demonstrated the functional interplay
between mGluR5s and NMDARs during ethanol with-
drawal induced neurotoxicity using organotypic hippo-
campal slices [38]. In addition, Olive [39] reported that
the high dose effect of MPEP can be due to mechanisms
not associated with mGluR5 modulation.
Any sedative or compromising effects on locomotor activ-
ities can produce confounding results in a behavioural study.
We recorded the locomotion of ethanol withdrawn and
ethanol naïve rats using multiple parameters, including basic
movement, fine movement, X ambulation (closed arm),
Y ambulation (open arm), closed arm entries, and the
number of lines crossed in the open field. Our data
shows that 20 days of chronic ethanol administration
results in a significant reduction in locomotor activities
of ethanol withdrawn rats compared to control rats
(Figure 1 and 5A). Ethanol fed rats showed a significant re-
duction in basic and fine movement, X and Y ambulation,
the number of entries produced in the closed arms of the
elevated plus maze and the number of lines crossed in
the open field compared to control rats. This ethanol
withdrawal induced hypolocomotion following chronic
ethanol exposure is synonymous with some previous
studies [40,41] and withdrawal induced hypoactivity is
an additional behavioural sign of ethanol withdrawal [12].
MPEP at 2.5 and 5 mg/kg significantly decreased basic
movement, fine movement, X ambulation, and Y ambula-
tion in the elevated plus maze. Additionally, neither doses
of MPEP (2.5 and 5 mg/kg) imposed any significant effect
on the open arm entries compared to the ethanol with-
drawal group, suggesting that the significant anxiolytic ef-
fect of low doses of MPEP recorded in the elevated plus
maze is due to the compromising effect on locomotion
causing an increase in time spent immobile on the open
arm of the maze rather than an increase in explorative be-
haviour. This compromising effect of MPEP on locomotor
activities at 2.5 mg/kg was also recorded in the open field
(Figure 5A). On the other hand, MPEP at 5 mg/kg com-
promised locomotion of ethanol withdrawn rats when
tested in the EPM. Thus, the significant effect of this dose
in reversing withdrawal anxiety observed in the EPM is
debatable. MPEP at 10 and 30 mg/kg had neither ameli-
orating nor compromising effects on ethanol withdrawal
induced hypolocomotion. Despite lack of significant
compromising effects of MPEP dosages on the locomotion
(Figures 3 and 6B), some reduction in the locomotion
of ethanol naïve rats at 20 and 30 mg/kg MPEP wasobserved, which is consistent with previous reports
with different behavioural tests [42,43]. Previous stud-
ies have reported a high abundance of mGluR5 in the nu-
cleus accumbens and striatum [44,45], which has been
heavily associated in mediating the motor effects of psy-
chostimulants in rodents [43,46,47]. Thus, the blockade of
mGluR5 in these sites could be responsible for the effects
observed in the locomotion.
Conclusions
Earlier studies and our study have reported significant
anti-anxiety effects of MPEP on non-ethanol dependent
rats in a number of assays in a dose range of 2.5 to
30 mg/kg [9,48]. Our study, using an elevated plus maze
and an open field, reported significant effects of MPEP at
10 mg/kg in reversing ethanol withdrawal induced anxiety.
Administration of MPEP at this dose also has no signifi-
cant effect on the locomotor activities of ethanol naïve
and ethanol withdrawn rats when tested in both behav-
ioural paradigms. Taken together, the anxiolytic effect of
10 mg/kg MPEP in attenuating withdrawal anxiety in this
study is convincing. Thus, we believe that the antagonism
of mGluR5 could provide an effective pharmacological
intervention in treating ethanol withdrawal induced anxiety.
However, the confounding effects of MPEP at high and low
doses still warrants further investigation to understand the
mechanism of MPEP better.
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